相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Virology
Florence Nicot et al.
Summary: This study evaluated a target capture SMRT sequencing protocol for SARS-CoV-2 Omicron variants and compared it to an amplicon SMRT sequencing protocol optimized for Omicron variants. The target capture protocol had a lower failure rate and higher genome coverage compared to the amplicon protocol, making it an efficient method for whole genome sequencing, genotyping, and mutation detection of SARS-CoV-2 Omicron variants.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Heui Man Kim et al.
Summary: The Omicron variant of SARS-CoV-2 has become dominant in South Korea since November 2021. While it causes low pathogenicity in healthy individuals, it leads to more severe symptoms and higher hospitalization rates in the elderly and immunocompromised. This study found that elderly individuals who received a third dose of vaccine had higher levels of SARS-CoV-2-specific antibodies and neutralizing antibodies against the Delta variant compared to those who received one or two doses. However, the neutralization antibody level against the Omicron variant was low, suggesting the need for a fourth dose of vaccination in the elderly to reduce the impact of the Omicron variant.
Article
Biochemistry & Molecular Biology
Hung Fu Tseng et al.
Summary: A test-negative case-control analysis using data from a diverse population in California, USA, demonstrates that vaccine efficacy of a three-dose regimen of the mRNA-1273 COVID-19 vaccine is reduced against infection with the Omicron SARS-CoV-2 variant in comparison to Delta, but that efficacy against hospitalization remained high for both variants.
Letter
Medicine, General & Internal
Khitam Muhsen et al.
Summary: During a surge of Covid-19 cases in Israel, a rapid deployment of BNT162b2 booster injections in long-term care facilities over a 3-week period in July resulted in a 71% decrease in infection rates and an 80% decrease in hospitalization rates, while general population infection rates were increasing.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Editorial Material
Medicine, General & Internal
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Ronen Arbel et al.
Summary: A retrospective analysis of data from Israel shows that a second booster shot of BNT162b2 in individuals aged 60 and over significantly reduces hospitalizations and deaths due to COVID-19.
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After administering the fourth dose of BNT162b2 vaccine to individuals aged 60 years and older during the period when the omicron variant was predominant, Israel observed lower rates of confirmed SARS-CoV-2 infection and severe Covid-19 compared to those who received only three doses. The protection against severe illness remained consistent, while the protection against confirmed infection decreased over time.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Gili Regev-Yochay et al.
Summary: Health care workers in Israel received a fourth dose of mRNA vaccine during the prevalence of the omicron variant. The fourth dose boosted antibody levels but did not surpass the maximum observed after the third dose. The vaccine demonstrated an efficacy of 31 to 43% against symptomatic disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Sivan Gazit et al.
Summary: This study examined the effectiveness of a fourth dose of the Pfizer-BioNTech mRNA vaccine compared to three doses over a 10-week period. The results showed that the fourth dose provided additional protection against SARS-CoV-2 infection and severe COVID-19 disease in the first three weeks. However, the relative effectiveness of the fourth dose against infection decreased over time.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Infectious Diseases
Xiao-Lin Jiang et al.
LANCET INFECTIOUS DISEASES
(2022)
Letter
Medicine, General & Internal
Michal Canetti et al.
Summary: A fourth dose of the BNT162b2 vaccine resulted in a smaller improvement in immunity compared to a third dose, and this improvement disappeared completely after 13 weeks.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Khitam Muhsen et al.
Summary: This cohort study found a significant inverse association between the third dose of the BNT162b2 vaccine and overall SARS-CoV-2 infection, COVID-19 hospitalizations, severe disease, and COVID-19-related deaths among LTCF residents during a massive surge caused by the Delta variant in Israel.
Letter
Infectious Diseases
Chee-Wah Tan et al.
Article
Microbiology
Panke Qu et al.
Summary: The newly emerged BA.2.75 variant of SARS-CoV-2 has 9 additional mutations in its spike protein compared to the ancestral BA.2 variant. It shows enhanced resistance to neutralizing antibodies, primarily due to the G446S and N460K mutations. Additionally, BA.2.75 exhibits enhanced cell-cell fusion, driven mainly by the N460K mutation.
CELL HOST & MICROBE
(2022)
Letter
Infectious Diseases
Qiu-Yan Xu et al.
JOURNAL OF INFECTION
(2022)
Letter
Infectious Diseases
Chloe Dimeglio et al.
JOURNAL OF INFECTION
(2022)
Article
Microbiology
Sabine Chapuy-Regaud et al.
Summary: Three commercially available assays for SARS-CoV-2 antibodies were evaluated with varying sensitivity for different stages of infection. The assays showed correlation with neutralizing antibody titers, but discrepancies were observed in certain scenarios.
MICROBIOLOGY SPECTRUM
(2021)
Article
Multidisciplinary Sciences
Dami A. Collier et al.
Summary: Elderly individuals, especially those above eighty, show lower immune responses and neutralization abilities against variants of concern after the first vaccine dose, but this improves after the second dose. They have higher frequencies of spike-specific memory B cells but reduced somatic hypermutation of class-switched cells. Production of interferon-gamma and interleukin-2 by SARS-CoV-2 spike-specific T cells is lower in older participants, predominantly by CD4 T cells.
Review
Cell Biology
Juliet M. Bartleson et al.
Summary: The COVID-19 pandemic poses a greater risk for severe disease and death in older adults and individuals with age-related metabolic and cardiovascular diseases. Interventions targeting immunosenescence may be crucial in reducing mortality and disability caused by the pandemic, ultimately improving complications associated with severe COVID-19 in individuals of all ages.
